IRESSA vs KISQALI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 19, 2026·How we rate

Possible drug interaction. IRESSA and KISQALI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	IRESSA	KISQALI
Rating	70/100	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	GEFITINIB	RIBOCICLIB SUCCINATE
Manufacturer	Astrazeneca	Novartis
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma	Breast Neoplasms

iressa kisqali

Rating

70/100

Pharmacy pays

—

Type

Active ingredient

GEFITINIB

RIBOCICLIB SUCCINATE

Manufacturer

Astrazeneca

Novartis

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma

Breast Neoplasms

Frequently asked questions

Which is better-rated, Iressa or Kisqali?

Iressa and Kisqali are tied at 3.5 out of 5 by our independent rating.

What is the difference between Iressa and Kisqali?

Iressa contains Gefitinib, while Kisqali contains Ribociclib Succinate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.